GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyxone AB (FRA:4CX) » Definitions » Research & Development

Cyxone AB (FRA:4CX) Research & Development : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cyxone AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Cyxone AB's Research & Development for the three months ended in Jun. 2024 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Cyxone AB Research & Development Historical Data

The historical data trend for Cyxone AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyxone AB Research & Development Chart

Cyxone AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only - - - - -

Cyxone AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cyxone AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyxone AB  (FRA:4CX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cyxone AB Research & Development Related Terms

Thank you for viewing the detailed overview of Cyxone AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyxone AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyxone AB (FRA:4CX) » Definitions » Research & Development
Comparable Companies
OSTO:2CUREX XSAT:WNT OSTO:DIABIO OSTO:LIDDS OSTO:ZICC XSAT:ALTE OSTO:FLUI OSTO:LPGO OSTO:QUIA XSAT:APTA VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
Hyllie Boulevard 34, Malmo, SWE, 215 32
Website
https://www.cyxone.com
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Cyxone AB Headlines

No Headlines